Nanobiotix (NBTX) Price & Analysis

Compare

93 Followers

NBTX Stock Chart & Stats

$24.52

-$0.03(-1.02%)

At close: Jan 08 4:00 PM EST

$24.52

-$0.03(-1.02%)

Day’s Range― - ―

52-Week Range$2.76 - $30.35

Previous CloseN/A

Volume23.08K

Average Volume (3M)113.58K

Market Cap

$1.01B

Enterprise Value$250.61M

Total Cash (Recent Filing)$28.82M

Total Debt (Recent Filing)$51.24M

Price to Earnings (P/E)―

Beta0.90

Next Earnings

Nov 18, 2025

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)N/A

Shares Outstanding47,943,150

10 Day Avg. Volume59,578

30 Day Avg. Volume113,577

Financial Highlights & Ratios

PEG Ratio-0.06

Price to Book (P/B)-1.99

Price to Sales (P/S)-11.28

P/FCF Ratio-6.42

Enterprise Value/Market Cap0.25

Enterprise Value/Revenue43.66

Enterprise Value/Gross Profit43.66

Enterprise Value/Ebitda-7.37

Forecast

1Y Price Target

$24.00

Price Target Upside-2.12% Downside

Rating ConsensusModerate Buy

Number of Analyst Covering1

EPS Forecast (FY)-0.5

Revenue Forecast (FY)$39.00M

Bulls Say, Bears Say

Bulls Say

Clinical ProgressThe first patient has been injected in an ongoing cohort study that adds standard-of-care chemotherapy to NBTXR3, indicating progress in research and development.

Financial StabilityA recent amendment of its licensing agreement with JNJ extends the company's cash runway to mid-2026, safeguarding the company's path through the interim analysis of the NANORAY-312 trial.

Partnership And CollaborationThe collaboration with JNJ and the totality of the NBTXR3 data are viewed as supportive with potential for large commercial opportunities.

Bears Say

Financial ConcernsInvestor focus is expected to remain on the company's cash runway and ongoing concerns about the balance sheet, implying financial stability is a key concern for stakeholders.

Investor UncertaintyInvestor focus will largely remain on the company's cash runway and the ongoing Phase III NANORAY-312 study in LA HNSCC.

Nanobiotix News

Nanobiotix price target raised to EUR 23 from EUR 20 at H.C. Wainwright

H.C. Wainwright raised the firm’s price target on Nanobiotix (NBTX) to EUR 23 from EUR 20 and keeps...

16d ago

NBTX

Nanobiotix enters royalty-based financing pact with HealthCare Royalty for $71M

Nanobiotix (NBTX) announced that it has entered into a royalty-based financing agreement with HealthCare Royalty, providing up to...

20d ago

NBTX

Nanobiotix provides update on JNJ-1900 after Johnson & Johnson transfer

Nanobiotix (NBTX) announced updates to the JNJ-1900 clinical development program. Nanobiotix has completed the transfer of NANORAY-312 sponsorship,...

27d ago

JNJ

NBTX

Nanobiotix Advances Curadigm Nanoprimer Platform with New Patents and Preclinical Data

Nanobiotix ( ($NBTX) ) has issued an announcement. On November 13, 2025, Nanobiotix announced significant advancements in its...

6d ago

NBTX

Nanobiotix Announces Updated Voting Rights and Share Capital

Nanobiotix ( ($NBTX) ) has shared an announcement. On November 14, 2025, Nanobiotix announced its updated voting rights...

6d ago

NBTX

Nanobiotix to Present at Jefferies London Healthcare Conference

Nanobiotix ( ($NBTX) ) has shared an announcement. On November 11, 2025, Nanobiotix announced its participation in the...

8d ago

NBTX

Nanobiotix’s Strategic Financing and Clinical Expansion Signal Strong Buy Opportunity

Analyst Swayampakula Ramakanth of H.C. Wainwright maintained a Buy rating on Nanobiotix, boosting the price target to €23.00....

16d ago

NBTX

Nanobiotix to Present at Key November Investor Conferences

An announcement from Nanobiotix ( ($NBTX) ) is now available. On November 3, 2025, Nanobiotix announced its participation...

17d ago

NBTX

Nanobiotix Secures $71 Million Royalty Agreement with HealthCare Royalty

Nanobiotix ( ($NBTX) ) has provided an announcement. On October 31, 2025, Nanobiotix announced a strategic royalty monetization...

20d ago

NBTX

Nanobiotix Transfers Phase 3 Trial Control to J&J, Updates on NBTXR3 Program

Nanobiotix ( ($NBTX) ) has issued an update. On October 24, 2025, Nanobiotix announced updates to its JNJ-1900...

27d ago

NBTX

Nanobiotix Updates Voting Rights and Share Capital Details

Nanobiotix ( ($NBTX) ) has shared an update. On October 15, 2025, Nanobiotix announced its voting rights and...

1M ago

NBTX

Nanobiotix SA ADR Reports Revenue Surge Amid Strategic Advances

Nanobiotix Sa ADR ( ($NBTX) ) has released its Q2 earnings. Here is a breakdown of the information...

2M ago

NBTX

Nanobiotix price target raised to EUR 20 from EUR 13 at H.C. Wainwright

H.C. Wainwright raised the firm’s price target on Nanobiotix (NBTX) to EUR 20 from EUR 13 and keeps...

2M ago

NBTX

Nanobiotix Reports Promising Phase 1 Results for Esophageal Cancer Treatment

Nanobiotix ( ($NBTX) ) has issued an announcement. On October 1, 2025, Nanobiotix announced promising initial data from...

2M ago

NBTX

NBTX FAQ

What was Nanobiotix Sa ADR’s price range in the past 12 months?

Nanobiotix Sa ADR lowest stock price was $2.76 and its highest was $30.35 in the past 12 months.

What is Nanobiotix Sa ADR’s market cap?

Nanobiotix Sa ADR’s market cap is $1.01B.

When is Nanobiotix Sa ADR’s upcoming earnings report date?

Nanobiotix Sa ADR’s upcoming earnings report date is Nov 18, 2025 which is 2 days ago.

How were Nanobiotix Sa ADR’s earnings last quarter?

Currently, no data Available

Is Nanobiotix Sa ADR overvalued?

According to Wall Street analysts Nanobiotix Sa ADR’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Nanobiotix Sa ADR pay dividends?

Nanobiotix Sa ADR does not currently pay dividends.

What is Nanobiotix Sa ADR’s EPS estimate?

Nanobiotix Sa ADR’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Nanobiotix Sa ADR have?

Nanobiotix Sa ADR has 47,943,150 shares outstanding.

What happened to Nanobiotix Sa ADR’s price movement after its last earnings report?

Currently, no data Available

Which hedge fund is a major shareholder of Nanobiotix Sa ADR?

Currently, no hedge funds are holding shares in NBTX

Nanobiotix Stock Smart Score

Neutral

Fundamentals

Return on Equity

―

Trailing 12-Months

Asset Growth

-42.92%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Nanobiotix Sa ADR

Nanobiotix (NBTX) is a clinical-stage biotechnology company specializing in the development of innovative cancer therapies. The company focuses on the research and commercialization of nanomedicine-based products to enhance the efficacy of radiotherapy and chemotherapy. NBTX's flagship product, NBTXR3, is a novel radio-sensitizer designed to improve the treatment outcomes for solid tumors by increasing the sensitivity of cancer cells to radiation. The company operates primarily in the oncology sector, leveraging cutting-edge nanotechnology to advance cancer treatment options.

Nanobiotix (NBTX) Earnings & Revenues

Historic Earnings Reports

NBTX Stock 12 Month Forecast

Average Price Target

$24.00

▼(-2.12% Downside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"1":"$1","7":"$7","13":"$13","19":"$19","25":"$25"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":24,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$24.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":24,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$24.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":24,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$24.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[1,7,13,19,25],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Dec<br/>2024","6":"Apr<br/>2025","9":"Jul<br/>2025","12":"Nov<br/>2025","25":"Nov<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,20.87,21.110769230769233,21.351538461538464,21.592307692307692,21.833076923076923,22.073846153846155,22.314615384615387,22.555384615384614,22.796153846153846,23.036923076923078,23.27769230769231,23.518461538461537,23.75923076923077,{"y":24,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,20.87,21.110769230769233,21.351538461538464,21.592307692307692,21.833076923076923,22.073846153846155,22.314615384615387,22.555384615384614,22.796153846153846,23.036923076923078,23.27769230769231,23.518461538461537,23.75923076923077,{"y":24,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,20.87,21.110769230769233,21.351538461538464,21.592307692307692,21.833076923076923,22.073846153846155,22.314615384615387,22.555384615384614,22.796153846153846,23.036923076923078,23.27769230769231,23.518461538461537,23.75923076923077,{"y":24,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":5.56,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.4,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.14,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.87,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.51,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.58,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.31,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.1,"date":1748736000000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":4.57,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.42,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":18.74,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":20.87,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >